Archive | Biopharmaceuticals Portfolio RSS feed for this section

No Confirmed Trading Bottom In Biotech Yet: Biotech ETF Review..Update-1

Update at Close 4/15….. Late Day Reversal To Green The NASDAQ Composite began a rally at 1P EDT and never stopped , moving up 62 points to close at 4034. Biotech ETFs followed step by step to end up in the green after a severe daily decline. The IBB ($217.6) ended up 1% after hitting […]

Leave a comment Continue Reading →

Biotech Rout Not Surprising: Surveying The Damage

Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in immunology, oncology and infectious disease were being launched. The life science sector […]

Leave a comment Continue Reading →

Risk Reversal: Bargain Hunting and FOMC Catalyst Perks Up Biotech Stocks… Update-1

Update 4/10 Abrupt Sell-Off –Failure to Confirm Bottom NASDAQ down 71 pts 1.7% All of yesterdays’ gains wiped out and we are back to January levels. Raise cash levels to 30% on life science portfolios.  Many high fliers and core holdings are selling off today after bullish action yesterday. See ALXN,GILD, IBB, ILMN, INCY,MDVN, PCYC, […]

Leave a comment Continue Reading →

Seeking A Technical Bottom For Biotech Stocks….. Update 4/9 Rally

NASDAQ Up 0.37% to 4133 Green screen alert with large cap biotechs. Time to cover hedges. Alexion (ALXN) up 2.23% Biogen (BIIB) Up 2.4% Celgene (CELG) up 3.61% Clovis Oncology (CLVS) up 2.85% Gilead (GILD) up 1.35% IBB up 1.96% Regeneron (REGN) up 3.99% Key Trends To Watch: April Update After Correction We provided a […]

Leave a comment Continue Reading →

Biotech Sell-Off Resumes: Caution Update 4/4

Update 4/4/14 Breach of Technicals-A Tad Below Early February Support Glut of Biotech IPOs Causing Indigestion? Momentum Days Are So Over NASDAQ Down 1.34% The volatile and speculative SPDR S&P Biotech XBI hit $136 in early trading down 2.28%.After a brief rally early this week to the $148 level volume picked up with sellers. The […]

Leave a comment Continue Reading →

Rayno Biopharmaceutical Stocks Q1 2014 Performance

Rayno Biopharmaceutical Portfolio 3/31/14 Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the early February technical levels. Use the two ETFs and FBIOX for re-balancing […]

Comments Off Continue Reading →